News

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...
Measles is one of 100 viruses that the team at VUMC is systematically making antibodies for by using single-cell sequencing — ...
The approach, which mimics how the body responds to a virus, could pave the way for a universal cancer vaccine.
The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the ...
In-N-Out CEO Lynsi Snyder announced she will be moving to Tennessee and bashed California on a recent podcast appearance.
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Newsom's office told KCRA the report is expected to be approximately 1,000 pages long and has apparently been underway for ...
Among other services, people could get the measles, mumps, and rubella or MMR vaccine for free. Renee Lyons of Atkins said ...
Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.
Lockheed Reports Earnings at a Tough Time. Drones and Defense Budgets Are a Worry. For the quarter, Wall Street is looking for earnings per share of about $6.41 from sales of $18.5 billion, according ...
Sanofi said it agreed to buy U.K. vaccine developer Vicebio for up to $1.6 billion, adding vaccine candidates for respiratory syncytial virus and human metapneumovirus to its pipeline.
The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...